炭素(Charcoal) - 药物靶点：NF-κB_在研适应症：瘙痒，慢性肾病_专利_临床

Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.
Study details include:
This event-driven study will have variable duration of approximately 40 months for the first participant being randomized and approximately 20 months for the last participant randomized.
The study intervention duration will vary ranging from approximately 20 to 40 months.
The assessment of scheduled visits will include 1 common end of study [EOS] visit and 3 follow-up visits) with a visit frequency of every 4 weeks for the first 6 months and then every 3 months.

开始日期2023-12-13

申办/合作机构

Sanofi

NCT06219967 / Completed临床4期IIT

Does a Soft Drink Mixture Improve Tolerance of Activated Charcoal in the Adult Poisoned Patient Without Affecting Efficacy: A Randomized Crossover Trial

Activated charcoal (AC) is an established, effective means of gastrointestinal decontamination. Providers give it to patients who have ingested something that is thought to be potentially poisonous to prevent it from being absorbed. However, one limitation to its use is palatability of the AC for the patient, potentially limiting how much, if any, is taken.
Other studies have suggested that mixing AC with various substances improves the rating on various scales (taste, etc). An important question is whether mixing the AC with other substance effects the ability of the AC to bind to xenobiotic in the gut. This small study investigates whether mixed cola with charcoal affected its ability to prevent the absorption of acetaminophen. It also performs a survery to see if participants preferred the AC-cola mixture. The investigators hypothesize that the AC will be equally as effective with cola as without. The investigators also hypothesize that participants will prefer the AC-cola mixture.

开始日期2023-01-04

申办/合作机构

SUNY Upstate Medical University

KCT0007834 / Not yet recruiting临床4期IIT

Effect of AST-120 and synbiotics on the gut microbiome and the muscle health in dialysis independent chronic kidney disease patients, a randomized-controlled trial

开始日期2023-01-02

申办/合作机构-

100 项与炭素相关的临床结果

登录后查看更多信息

100 项与炭素相关的转化医学

登录后查看更多信息

100 项与炭素相关的专利（医药）

登录后查看更多信息

319

项与炭素相关的文献（医药）

2023-07-10·Kidney research and clinical practice

Factors associated with gait speed: results from the RolE of AST120 (Renamezin) in sarCOpenia preVEntion in pRe-dialYsis chronic kidney disease patients (RECOVERY) study.

Article

作者: Song, Sang Heon ; Kim, Jun Chul ; Kim, Su Hyun ; Han, Miyeun ; An, Won Suk ; Kang, Seock Hui ; Cha, Ran-Hui

Background:

Gait speed is an important measure of functional ability. This study aimed to investigate the factors associated with gait speed in patients with chronic kidney disease. The study focused on sarcopenic components, plasma uremic or inflammatory marker levels, and quality of life effects.

Methods:

The RolE of AST120 (Renamezin) in sarCOpenia preVEntion in pRe-dialYsis chronic kidney disease patients is a 48-week, randomized controlled, parallel-group, open-label, multicenter trial to determine the role of Renamezin (Daewon Pharmaceutical Co., Ltd.) in patients with chronic kidney disease. The participants were classified into four groups according to gait speed: ≤0.8, 0.8-1.0, ≤1.0-1.3, and ≥1.3 m/sec. Linear regression analysis was performed to identify the factors associated with gait speed.

Results:

The group with a gait speed of ≤0.8 m/sec was the oldest and had the highest proportion of participants with low education level and medical aid. Participants with a gait speed of ≤0.8 m/sec showed the lowest physical and mental component scale scores. The interleukin-6 (IL-6) level tended to be the higher trend in the lowest gait speed group. In the multivariate linear regression analysis adjusted for age, sex, diabetes mellitus, and estimated glomerular filtration rate, insurance status, handgrip strength, IL-6 level, hemoglobin level, mental component scale score, and physical component scale score were significantly associated with gait speed.

Conclusion:

In conclusion, gait speed is associated with handgrip strength, IL-6 level, and various components of quality of life in predialysis chronic kidney disease patients.

2023-06-22·Cureus

Effect of Charcoal, Probiotic, and Chlorhexidine Mouthwashes on Mechanical Properties and Surface Characterization of Ceramic-Coated Nickel-Titanium Orthodontic Arch Wires: A Comparative In-Vitro Study

Article

作者: Ranganayakulu, Inuganti ; Ramya, Peketi ; Raghu Ram, Rsvm ; Sunil, Ghanta ; Susanthi, Bokka

AIM AND OBJECTIVES:

To determine the impact on the mechanical properties and surface features of ceramic-coated nickel-titanium (CC-Ni-Ti) archwires when subjected to charcoal, probiotic, and chlorhexidine mouthwashes in in vitro conditions.

MATERIALS AND METHODS:

Eighty samples of 25 mm were cut from the posterior end of preformed maxillary 0.016'' CC-Ni-Ti super elastic archwires (Koden Company, USA) and distributed into four equal groups. Each group of wires was immersed in artificial saliva (Wet Mouth Mouthwash, ICPA Health Products Ltd., India) (control), charcoal mouthwash (Hello activated charcoal extra freshening mouthwash, Hello Products LLC, USA), probiotic mouthwash (Perfora, Probiotic Rinse, India), and 0.2% chlorhexidine gluconate mouthwash (Sensorange, Orange Biotech, Pvt., Ltd., India) (experimental groups) for 90 min at 37 °C. All samples were taken out of their respective solutions and washed with distilled water prior to testing. A three-point bending test was performed on 15 samples from each group using a universal testing device. During the loading and unloading of the archwires, the yield strength (YS), flexural modulus of elasticity (E), and spring back ratio (YS/E) were calculated. The remaining five wires from each group were observed under the scanning electron microscope (SEM) for surface topography evaluation.

RESULTS:

The mean differences of loading YS, E, and YS/E between chlorhexidine and charcoal are 302.91 MPa, 4.28 GPa, and 0.0004, whereas unloading values are 172.32 MPa, 4.16 GPa, and 0.0003, respectively, with a statistical significance of <0.001 in terms of YS and E. The mean differences of loading YS, E, and YS/E between charcoal and probiotic are 305.36 MPa, 4.54 GPa, and 0.0005, whereas unloading values are 173.77 MPa, 3.66 GPa, and 0.0003, respectively, with a statistical significance of <0.001 in terms of YS and E. The mean differences of loading YS, E, and YS/E between chlorhexidine and probiotic are 2.45 MPa, 0.26 GPa, and 0.00007, whereas unloading values are 1.44 MPa, 0.49 GPa, and 0.0000533, respectively, with no statistical significance of >0.001 in terms of YS, E, and YS/E. Surface topography alteration was clearly appreciated in the charcoal and probiotic mouthwash groups compared to charcoal mouthwash.

CONCLUSIONS:

Loading and unloading of 0.016" ceramic-coated nickel-titanium archwires showed an increase in mechanical properties except for the spring back ratio on exposure to chlorhexidine, probiotic, and charcoal mouthwashes. Chlorhexidine and probiotic mouthwashes had a higher yield strength and flexural modulus of elasticity in comparison with charcoal mouthwash and artificial saliva on 0.016" ceramic-coated nickel-titanium archwires. More corrosive changes were seen on 0.016" ceramic-coated nickel-titanium archwires when immersed in chlorhexidine, followed by probiotic and charcoal mouthwashes.

2023-02-01·Journal of cachexia, sarcopenia and muscle

The G protein‐coupled receptor ligand apelin‐13 ameliorates skeletal muscle atrophy induced by chronic kidney disease

Article

作者: Enoki, Yuki ; Hamamura, Yuna ; Nagai, Tomoya ; Osa, Sumika ; Watanabe, Hiroshi ; Maruyama, Toru ; Nakamura, Hideaki ; Matsumoto, Kazuaki ; Taguchi, Kazuaki

Abstract:

Background:

Targeting of the apelin–apelin receptor (Apj) system may serve as a useful therapeutic intervention for the management of chronic kidney disease (CKD)‐induced skeletal muscle atrophy. We investigated the roles and efficacy of the apelin–Apj system in CKD‐induced skeletal muscle atrophy.

Methods:

The 5/6‐nephrectomized mice were used as CKD models. AST‐120, a charcoal adsorbent of uraemic toxins (8 w/w% in diet), or apelin (1 μmol/kg) was administered to CKD mice to investigate the mechanism and therapeutic potential of apelin on CKD‐induced skeletal muscle atrophy. The effect of indoxyl sulfate, a uraemic toxin, or apelin on skeletal muscle atrophy was evaluated using mouse myoblast cells (C2C12 cells) in vitro.

Results:

Skeletal muscle atrophy developed over time following nephrectomy at 12 weeks, as confirmed by a significant increase of atrogin‐1 and myostatin mRNA expression in the gastrocnemius (GA) muscle and a decrease of lower limb skeletal muscle weight (P < 0.05, 0.01 and 0.05, respectively). Apelin expression in GA muscle was significantly decreased (P < 0.05) and elabela, another Apj endogenous ligand, tended to show a non‐significant decrease at 12 weeks after nephrectomy. Administration of AST‐120 inhibited the decline of muscle weight and increase of atrogin‐1 and myostatin expression. Apelin and elabela expression was slightly improved by AST‐120 administration but Apj expression was not, suggesting the involvement of uraemic toxins in endogenous Apj ligand expression. The administration of apelin at 1.0 μmol/kg for 4 weeks to CKD mice suppressed the increase of atrogin‐1 and myostatin, increased apelin and Apj mRNA expression at 30 min after apelin administration and significantly ameliorated weight loss and a decrease of the cross‐sectional area of hindlimb skeletal muscle.

Conclusions:

This study demonstrated for the first time the association of the Apj endogenous ligand–uraemic toxin axis with skeletal muscle atrophy in CKD and the utility of therapeutic targeting of the apelin–Apj system.

1

项与炭素相关的新闻（医药）

2022-07-26

·生物谷

Front Nutr：酸性活性炭或能帮助预防机体体重增加及胰岛素耐受性的发生

来自日本信州大学医学院等机构的科学家们通过研究发现，可食用的活性炭或许还会吸收饮食中过多的脂肪，文章中，研究人员验证了来自信州大学的赤松树所产生的酸性活性炭对小鼠的影响和安全性。随着人类饮食习惯的西方化，目前全球各地肥胖人口的比例都在不断增加，肥胖是一个人类面临的迫切的健康问题，同时也是导致多种疾病发生的风险因素，比如糖尿病、脂肪肝和血脂异常等。众所周知，可食用的活性炭能在肠道中吸收尿液毒素和胆汁酸，并以粪便的形式将其排出体外。近日，一篇发表在国际杂志Frontiers in Nutrition上题为“Acidic Activated Charcoal Prevents Obesity and Insulin Resistance in High-Fat Diet-Fed Mice”的研究报告中，来自日本信州大学医学院等机构的科学家们通过研究发现，可食用的活性炭或许还会吸收饮食中过多的脂肪，文章中，研究人员验证了来自信州大学的赤松树所产生的酸性活性炭对小鼠的影响和安全性。当小鼠被给予正常饮食和高脂肪饮食长达12周时，喂食高脂肪饮食的小鼠相比正常饮食的小鼠而言能体重会明显增加，从另一方面来讲，当酸性活性炭与高脂肪饮食混合后，以同样的方式喂食小鼠，其体重增加的程度几乎与正常饮食相同，这意味着，因高脂肪饮食所导致的体重增加会被完全抑制。当酸性活性炭与高脂肪饮食一起让小鼠摄入时，其粪便中胆汁酸、胆固醇、甘油三酯和脂肪酸的水平要比常规高脂肪饮食增加大约2-4倍，这或许会被认为其会促进在粪便中的排出，此外，研究人员并未观察到酸性活性炭对小鼠机体胃肠道或肺部的损伤。酸性活性炭或能帮助预防机体体重增加及胰岛素耐受性的发生。图片来源：Naoki Tanaka, Shinshu University 将酸性活性炭与高脂肪食物一起摄入，或在进食前摄入酸性活性炭或许能有效预防机体体重增加，基于从这项研究中得到的研究结果，研究人员希望能促进开发更有效且安全性的酸性活性炭，同时与当地和全球的公司合作，来开发出更有效的预防性措施来抵御疾病。长期以来，制作木炭在信州广泛流行，利用这类技术所产生的活性炭同样被用于除臭和净水，本文研究表明，来自赤松树中的酸性活性炭或能预防因高脂肪饮食所导致的小鼠体重增加和胰岛素耐受，通过将酸性活性炭加入到日常饮食中，或许就能有效预防人类肥胖、脂肪肝和糖尿病的发生，这些疾病近年来在全球的流行率不断增加。后期研究人员将会继续深入研究来讲来自赤松树中的酸性活性炭应用于医疗健康研究领域，综上，本文研究结果表明，酸性活性炭或许具有预防肥胖、代谢综合征及其相关疾病的重要特性。（生物谷Bioon.com）原始出处： Xuguang Zhang, Pan Diao, Hiroaki Yokoyama, et al. Acidic Activated Charcoal Prevents Obesity and Insulin Resistance in High-Fat Diet-Fed Mice, Frontiers in Nutrition (2022). DOI: 10.3389/fnut.2022.852767

100 项与炭素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A07BA01	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
瘙痒	中国台湾	-	2020-07-26
慢性肾病	日本	Mitsubishi Tanabe Pharma Corp.	1991-10-04

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
炎症性肠病	临床3期	奥地利	OCERA Therapeutics LLC	2006-03-01
炎症性肠病	临床3期	比利时	OCERA Therapeutics LLC	2006-03-01
炎症性肠病	临床3期	捷克	OCERA Therapeutics LLC	2006-03-01
炎症性肠病	临床3期	法国	OCERA Therapeutics LLC	2006-03-01
炎症性肠病	临床3期	德国	OCERA Therapeutics LLC	2006-03-01
炎症性肠病	临床3期	匈牙利	OCERA Therapeutics LLC	2006-03-01
炎症性肠病	临床3期	荷兰	OCERA Therapeutics LLC	2006-03-01
炎症性肠病	临床3期	波兰	OCERA Therapeutics LLC	2006-03-01
炎症性肠病	临床3期	英国	OCERA Therapeutics LLC	2006-03-01
肠瘘	临床3期	美国	OCERA Therapeutics LLC	2006-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


RolE of AST120 in sarCOpenia preVEntion in pRe-dialYsis chronic kidney disease patients (ERA2022)	N/A	慢性肾病 plasma uremic \| inflammatory markers	150	AST120	壓鹽簾鬱鑰餘願憲憲範(鹹夢繭淵醖夢膚壓鹽網) = 淵膚壓廠鑰鹹鹹蓋壓鹽艱襯簾鏇襯獵齋鏇鑰窪 (觸網艱襯糧選築衊鏇糧, 0.3)	-	2022-05-03
				AST120	壓鹽簾鬱鑰餘願憲憲範(鹹夢繭淵醖夢膚壓鹽網) = 構憲淵鹽憲壓獵廠築壓艱襯簾鏇襯獵齋鏇鑰窪 (觸網艱襯糧選築衊鏇糧, 0.3)
AST-120 (ASN2019)	N/A	-	225	AST-120	觸壓膚憲膚齋鑰積廠獵(醖襯衊壓範顧醖餘襯艱) = 糧淵簾遞糧襯製網壓糧簾鹹醖簾憲鬱繭網襯夢 (鹹膚顧鏇齋窪選糧衊艱 ) 更多	积极	2019-11-05
ASN2019	N/A	indole \| indoxyl sulfate	30	AST-120 6 gram/day	齋衊廠膚憲鬱願構鏇顧(憲艱願鬱鹽觸膚積蓋壓) = did not change during study period 製積網顧醖淵淵遞蓋壓 (艱廠積醖簾憲網夢顧積 ) 更多	积极	2019-11-05
SP574 (ERA2019)	N/A	indoxyl sulfate	-	AST-120	選鬱獵鑰願繭窪鬱襯醖(廠鹽膚壓遞範壓餘範簾) = 製繭糧壓鏇膚壓簾積鏇淵鑰遞獵淵衊鬱鹹遞鏇 (構繭獵觸觸願繭襯壓鏇 ) 更多	积极	2019-06-13
NCT00500682 \| NCT00501046 (EPPIC, Pubmed \| BMC Nephrol)	临床3期	慢性肾病	2,035	AST-120	觸簾襯廠蓋製餘鬱製構(鑰遞蓋築艱餘鹽構醖鏇): Hazard Ratio = 0.74 (95% CI, 0.56 ~ 0.97)	-	2016-09-30
				Placebo
NCT00501046 (EPPIC-2, Pubmed \| J Am Soc Nephrol) 人工标引	临床3期	慢性肾病	2,035	AST-120	淵簾膚壓繭製網憲壓範(鹹製觸夢餘顧獵廠願襯): HR = 0.91 (95% CI, 0.74 ~ 1.12), P-Value = 0.37	不佳	2015-07-01
				Placebo
NCT00500682 (CTgov)	临床3期	慢性肾病	1,020	AST-120 (AST-120)	壓淵蓋顧構鏇襯窪觸網(積獵夢襯簾淵簾艱衊獵) = 觸廠襯糧遞構艱鬱鑰糧壓艱積憲艱襯願積繭遞 (積齋夢選餘淵艱鹹廠選, 築蓋艱鬱遞鑰窪鏇鹽襯 ~ 膚醖糧範構襯遞壓鑰簾) 更多	-	2015-03-02
				Placebo (Placebo)	壓淵蓋顧構鏇襯窪觸網(積獵夢襯簾淵簾艱衊獵) = 壓繭淵廠餘觸夢鏇餘網壓艱積憲艱襯願積繭遞 (積齋夢選餘淵艱鹹廠選, 選餘簾簾鹹觸範窪願築 ~ 積範淵鑰齋窪淵觸醖齋) 更多
NCT00501046 (CTgov)	临床3期	慢性肾病	1,015	AST-120 (AST-120)	願網蓋觸衊鑰鹹廠範糧(構鹽糧餘艱糧衊鹹觸齋) = 餘襯網遞鬱憲觸蓋網壓網淵淵積蓋衊蓋觸壓憲 (獵壓襯鹹獵築醖積簾鹽, 窪遞範顧範膚願憲網鏇 ~ 鏇憲築製積範鬱壓願選) 更多	-	2015-03-02
				Placebo (Placebo)	願網蓋觸衊鑰鹹廠範糧(構鹽糧餘艱糧衊鹹觸齋) = 齋鹽願鹽觸夢膚鑰範遞網淵淵積蓋衊蓋觸壓憲 (獵壓襯鹹獵築醖積簾鹽, 積鹹夢繭鑰遞積鑰遞夢 ~ 醖襯醖顧餘鬱鹹醖蓋鹹) 更多
ASN2013	N/A	尿毒症维持 indoxyl sulfate	20	AST-120 6g/day	築齋選製簾積膚鏇顧艱(壓齋鹽膚糧鬱鹹廠繭襯) = 遞鹹觸鑰鏇鏇憲襯襯糧憲願鑰鏇遞窪網鬱積壓 (壓糧觸鹹蓋顧餘獵觸艱, 1.25 ~ 1.98)	积极	2013-11-05
				AST-120	築齋選製簾積膚鏇顧艱(壓齋鹽膚糧鬱鹹廠繭襯) = 鬱膚鬱繭餘糧廠蓋築夢憲願鑰鏇遞窪網鬱積壓 (壓糧觸鹹蓋顧餘獵觸艱, 1.38 ~ 2.89)